ACTAVIS SUBUTEX - AN OVERVIEW

The concomitant use of buprenorphine and CYP3A4 inducers can lower the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], likely resulting in diminished efficacy or onset of a withdrawal syndrome in individuals who have designed Actual physical dependence to buprenorphine.Warning people that SUBUTEX may perhaps impair the psychological or p